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Background: The COVID-19 outbreak brought an unprecedented challenge to the world.
Knowledge in the field has been increasing exponentially and the main allergy societies have
produced guidance documents for better management of allergic patients during this period.
However, few publications so far have provided real-life data from the allergy community con-
cerning allergy practice during the COVID-19 outbreak. Therefore, we proposed an international
survey on the management of allergic patients during the current pandemic.
Methods: We performed an online survey undertaken to reach out the worldwide allergy com-
munity by e-mail and social media. The web-based questionnaire contained 24 questions covering
demographic data from the participants, clinical practice during this period, and questions related
to the new international classification and coding tools addressed for COVID-19. It was circulated
for 8 weeks and had anonymous and volunteer context.
Results: Data are presented for 635 participants from 78 countries of all continents. Allergists with
long-term professional experience were the main audience. As expected, we received many re-
sponses as “I have no data” or “I don’t know” to the questions of the survey. However, most with
more experience on managing allergic patients during the pandemic agreed that patients
suffering from allergic or hypersensitivity conditions have no increased risk of contracting COVID-
19 or developing SARS CoV-2. Also, participants mentioned that none of the allergy treatments
(inhaled corticosteroids, allergen immunotherapy, biological agents) increased the risk of con-
tracting COVID-19 infection including severe presentations.
Conclusion: The data presented are a starting point in the process of getting feedback on all the
recommendations provided by the allergy societies; it could also be the basis of new strategies to
support health professionals while new COVID-19 specific treatments and vaccines are being
explored. The information here presented intends to be helpful to the community but represents apital Sírio-Libanês, Brazil
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helpful to health systems.
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Dynamic trends of the COVID-19 pandemic
The current outbreak of the novel coronavirus
disease 2019 (COVID-19), apparently began in
Hubei Province of the People’s Republic of China,
with the first reports dated at the end of 2019.
China bore the large burden of morbidity and
mortality before February 2020. The epidemic has
rapidly spread to other countries, and the World
Health Organization (WHO) Emergency Commit-
tee declared a global health emergency on 30
January 2020. Europe became the epicentre of the
epidemic in early April 2020, and due to the
number of countries reporting cases, WHO
considered the situation as a pandemic. The
United States followed the trend of being consid-
ered the centre of the pandemic in March 2020.
Due to the devastating numbers of hospitalizations
and deaths in Latin American countries, WHO
declared this region as the epicentre of the
pandemic in early June. The case detection rate is
increasing exponentially; in mid-July 2020 the
number of COVID-19 cases surpassed 16 000 000
globally, with more than 650 000 deaths1,2 (Fig. 1).
COVID-19 is due to an enveloped single-
stranded large RNA virus named the severe
acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Observations so far suggest a mean incu-
bation period of 5 days and a median incubation
period of 3 days.3 The proportion of individuals
infected by SARS-CoV-2 who remain asymptom-
atic throughout the course of infection has not yet
been definitely determined, but is likely to be
more than two-thirds. In symptomatic patients, the
clinical manifestations of the disease usually start
after less than a week. The infection can progress
to severe chest symptoms corresponding to
pneumonia in 75% of patients.3 The mortality ratescomorbid conditions have been associated with
even higher mortality rates (up to 15%),
suggesting particularly susceptible populations.5
Although COVID-19 appears to have a milder
course and less aggressive attack rate in children,
the outbreak is spreading fast and deaths have
been reported in all ages.
The COVID-19 pandemic drove state, local, and
territorial public health agencies to enact emer-
gency actions to protect and secure their nations’
health. These agencies routinely make difficult
decisions about how to respond effectively to the
dynamic trends of the pandemic, such as imple-
menting nonpharmacological interventions and
addressing the needs of populations at-risk. Many
public health actions have been taken in different
countries and world regions in order to limit the
transmission. These actions generally follow the
recommendations issued by WHO, which aims are
to: (i) interrupt human-to-human transmission
including reducing secondary infections, prevent-
ing transmission amplification events, and pre-
venting further international spread; (ii) identify,
isolate, and care for patients early; identify and
reduce transmission from the animal source; (iii)
address crucial unknowns regarding clinical
severity, diagnosis, magnitude of transmission and
infection, treatment options; (iv) communicate
critical risk and accurate information to all com-
munities; (v) minimize the burden of the conditions
related to the pandemic through multisectoral
partnership.6,7
A combination of public health measures is
crucial to prevent further spread at the interna-
tional level, such as rapid identification, diagnosis
and management of cases, identification and
follow up of the contacts, infection prevention and
control in health care settings, implementation of
Volume 14, No. 2, February 2021 3health measures for travellers, awareness raising in
the population and risk communication. Diag-
nostic testing for COVID-19 is critical to track the
SARS-CoV-2, inform case management, under-
stand its epidemiology and trends, and suppress
transmission. In fact, the concern is higher in low-
and middle-income countries, where health re-
sources are limited and reduced means of testing
hampers the diagnosis.7Fig. 1 World Health Organization report per region based on confirm
Allergy & COVID-19 international surveyAllergy & COVID-19: evidence-based data are
missing
As in other fields, knowing what is effective re-
quires scientific evidence. Yet, the evidence base
that informs the actions of public health agencies
and institutions in preparing for and responding to
emergencies is limited and heterogeneous and
fails to meet the needs of public health emergency
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Table 1. Responders to the international survey, response rates, demographic characteristics and allergy practice during the COVID-19 pandemic (NA¼ North America, LA ¼ Latin America,


















Volume 14, No. 2, February 2021 7Knowledge in the field has been increasing
exponentially in the last year due to the needs of
better understanding the many aspects of this
pandemic. Although there is still no specific treat-
ment for COVID-19, knowledge in the field is
constantly evolving. Remarkable is the increase of
the number of publications found when “COVID-
19” term is searched in PUBMED. It jumped up
from 3 publications in 2019 to 32 992 documents
by July 2020.9 All the main allergy societies have
been making efforts to promote better
management of allergic patients during the
pandemic by producing recommendations and
guidance documents.10–15 However, even with
the incremental number of publications over the
last months and the efforts of the allergy
academies, few publications so far have provided
real-life data from the allergy community con-
cerning allergy practice during the COVID-19
outbreak.16 Therefore, in order to provide real-
life data from the allergy community and poten-
tially support the implementation of evidence-
based specific recommendations, we proposed
an international survey on the management of
allergic patients during the current pandemic.MATERIAL & METHODS
The allergy community engagement: the allergy &
COVID-19 international survey
We developed a web-based survey in English,
to reach out to the allergy community worldwide.
An online questionnaire was constructed using
GoogleDocs, enabling responses to be recorded
in a unique database (Annex 1). We launched an
introduction letter containing a link to the
questionnaire unique to each participant. We
received help from a number of relevant
international and national societies, including
World Allergy Organization (WAO), Italian Society
of Allergology and Clinical Immunology (SIAIC),
and French Association for Continuing Education
in Allergology (ANAFORCAL) in distributing the
survey among their members. The link directed
respondents to a page explaining the purpose of
the survey. The survey was disseminated by e-
mail and social media. The online questionnaire
was beta-tested and launched via Internet on 20
April 2020 and closed 8 weeks later (on 22 June
2020). A reminder was sent out after 4 and 7weeks. The survey had anonymous and voluntary
standard.
Of the 24 questions (Annex 1), 7 covered
demographic data from the participants, 4 were
related to clinical practice during this period, 12
covered data related to the management of
allergic patients, including specific treatments
such as allergen immunotherapy (AIT) and
biological agents, and 1 related to the new
international classification and coding tools
addressed to COVID-19 morbidity and mortality
data recording.
RESULTS
Giving voice to the allergy community during the
COVID-19 pandemic
Surveying the international allergy community
Data are presented for 635 participants
(Table 1) from 78 countries who completed the
survey (Fig. 1). The countries were aggregated
according to world regions: North America (NA),
Latin America (LA), Europe (EU), Africa and
Middle East (AFR/ME), Asia Pacific (AP) and
across the global sample. As shown in Fig. 1 and
Table 1, all global regions were represented in
the survey. The proportion of respondents was
lowest for AFR/ME (6.1%) and highest for EU
(45.2%).
Ninety-seven percent (97%) of participants had
long-term (>20 years) professional experience
(Table 1); 74.1% of this group reported having
more than 10 years of professional experience in
allergic and hypersensitivity conditions; and
nearly two-thirds (74.5%) spent more than 15 h
per week seeing allergic patients.
Data related to participating countries, number
of participants from each country, mean age of
respondents, sex ratio, specialty, professional
experience, percent of professionals who spend
more than 15 h/week looking after patients
suffering from allergic and hypersensitivity dis-
eases, work setting, information related to the
lockdown, and use of telemedicine are available in
Table 1.
COVID-19 and allergy practice
Although some countries/regions did not adopt
an official lockdown or were in lockdown at the
8 Tanno et al. World Allergy Organization Journal (2021) 14:100515
http://doi.org/10.1016/j.waojou.2021.100515time of the survey, 58.5% of respondents reported
an official lockdown for at least 6 weeks in their
countries. As shown in Table 1, the practice of
allergology varied widely, having general similar
distribution of activities: 26.9% of participants
carried on seeing patients frequently with
reduction of the schedule, the same proportion
stopped seeing patients but utilized
telemedicine, and 25.9% decided to see only
emergency or specific cases (AIT or biological
agents’ administration, for example). Allergy
practice during the pandemic varied according
to the region (or regions). The use of
telemedicine was more frequent in NA (41.2%)
and lower in AP (28.3%) during the period of the
study. From overall 549 participants who used
telemedicine, most considered it as having
acceptable (43.7%) or good (29.9%) effectiveness
(Fig. 2).
When asked about epidemiological data
regarding allergic patients affected by COVID-19,
most of the doctors reported having no data.
However, 28.7% of the respondents mentioned
allergic patients who tested positive with no


























Not at all effective
Fig. 2 Implementation and effectivity of telemedicine according to the
LA ¼ Latin America, EU ¼ Europe, AFR/ME ¼ Africa and Middle East,patients with symptomatic and proven COVID-19.
Most of the participants reported less than 1% of
symptomatic COVID-19 in patients affected by
different allergic and hypersensitivity conditions
(Fig. 3).
According to the majority of respondents,
allergic patients were neither at risk of contracting
COVID-19 (53.4%) nor for developing severe
manifestations, including severe acute respiratory
syndrome (SARS) (46.1%). Two hundred twenty-
nine (36.1%) participants agreed that asthmatic
patients are at risk of developing SARS. Questions
regarding impact of anti-allergic (eg, biological)
agents on COVID-19 prevalence were most
commonly (58%) answered with “I have no data/I
don’t know". Although the survey showed many
responses of “I don’t know” to the questions pre-
sented in Table 2, 62.4% of participants found that
allergy treatment had no impact on COVID-19
presentation. The proportion was lower for the
experience regarding the risk of SARS and the use
of these drugs: 46.8% for inhaled corticosteroids
with or without long-acting beta agonist (LABA),
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Allergy & COVID-19 international survey (NA¼ North America,







Fig. 3 Allergy & COVID-19 survey. Number of responses per world region (NA¼ North America, LA ¼ Latin America, EU ¼ Europe, AFR/
ME ¼ Africa and Middle East, AP ¼ Asia Pacific)
Volume 14, No. 2, February 2021 9general, the responses between world regions
followed similar proportions (Table 2, Fig. 4).
From overall responses, 36.2% agreed that in-
dividuals with COVID-19 undergoing treatment
with biological agents or AIT are not at risk of
developing more adverse reactions due to these
drugs; 4.3% disagreed with this statement; and
61.6% mentioned having no information (Table 2).
Three hundred and eight respondents (48.5%)
were still not aware of the updates on the WHO
International Classification (ICD)-10 and ICD-11
COVID-19 classification and coding, with signifi-
cant regional differences.DISCUSSION
Lessons from the field
The COVID-19 outbreak brought an unprece-
dented challenge to the world. It changed
dramatically the landscape of how medicine was
practiced, forcing fast and incremental adaptation
of local, regional, and national health systems in
order to follow the public health emergency re-
sponses to the dynamic trends of the outbreak.
Facing the high contagious global pandemic, de-
cisions were key in order to limit the transmissionand provide quality care for allergic patients. This
first worldwide survey assessing the real-life data
from the allergy community provided a snapshot
of how allergy is being practiced during the
COVID-19 pandemic.
There is no doubt that specific actions have
proven to be essential to prevent transmission
such as social distancing, use of personal protec-
tive equipment, and specific personal hygiene
measures such as washing hands. Elective health-
care visits and procedures were postponed by
considering risk and benefits individually. Due to
social distancing recommendations, most of the
allergy community could benefit from e-health
tools and implementation of e-consultations when
possible.17,18 The use of e-health tools had to
follow national regulations. Clinicians considered
telemedicine suboptimal, nonetheless adequate
for the period of pandemic.
As far as we are dealing with a new virus with
potential contagious and lethal pattern, knowl-
edge in the field had to evolve quickly. However,
as expected, the health professionals gained pro-
gressively more experience of dealing with allergic
patients during this peculiar period. Although
most of the respondents were experienced























































Are ALLERGIC patients more at risk for severe symptoms
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Are individuals with COVID-19 under treatment with
BIOLOGICAL AGENTS or AIT at risk of developing more







































Are you aware of the updates on International
Classification of Diseases (ICD)-10 and ICD-11 in order to













Table 2. Responses of the Allergy & COVID-19 international survey according to the global regions, based on the experience of the allergy
community
Volume 14, No. 2, February 2021 11allergists, we observed a considerable percentage
of responses of “I don’t know” or “I have no data”
across the questions of the survey. In fact, the re-
sponses covered a specific period of the pandemic
as demonstrated in Fig. 3, and it is expected that
the allergy community may gain more knowledge
and experience in the field as science progresses
and more data are generated.
WHO has been recommending the testing of
symptomatic and asymptomatic subjects in order
to map the real extent of the pandemic and the
tailoring of preventive actions.19 However, many
areas in the world are experiencing a severe
shortage of test supplies for healthcare workers
and patients. This also may contribute to the “I
have no data” responses since most of the
questions of the survey inquired about patients
with proven COVID-19.
Although the early published data demon-
strated that asthma was not a strong risk factor for
severe COVID-19 disease, the actual risk is not
known and may evolve with additional data
reporting.20–22 In the survey, according to the
experience of the participants, most agreed that
patients suffering from allergic and
hypersensitivity conditions are not at higher risk
of contracting COVID-19 infection nor devel-
oping severe manifestations, such as SARS.
Although the US Centers for Disease Control and
Prevention (CDC) advises that “people with mod-
erate to severe asthma may be at higher risk of
getting sick from COVID-19. COVID-19 can affectyour respiratory tract (nose, throat, lungs), cause an
asthma attack, and possibly lead to pneumonia
and acute respiratory disease”,23 more recent data
indicate that allergic asthma may not be a potent
risk factor, particularly when well controlled, but
that non-allergic asthma may be a high risk fac-
tor.24-26
Because the development of manifestations and
evolution of COVID-19 are highly dependent on
the individual immune status and inflammatory
response, some hypotheses have emerged
regarding the allergic immune patterns (T2
inflammation mostly) and infection pro-
inflammatory response (mainly T1). Allergy,
atopy, or asthma, which can be considered the
clinical hallmarks of the Th2 immune orientation,
have been so far poorly investigated in COVID-19
patients, and often have not been included, or are
under-represented, neither among risk factors for
more severe evolution nor within the baseline
recurrent clinical features of COVID-19 patients.
Although we still do not have objective data to
prove how this balance can impact the clinical
pattern, respiratory allergies and asthma were not
reported as risk factor for SARS-COV-2 infec-
tion.16,24–29
Asthmatic patients should continue their base-
line treatment according to current asthma
guideline-based recommendations. There is no
evidence which contraindicates the use of nasal or
inhaled corticosteroids in any case. Inhaled corti-
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Use of INHALED CORTICOSTEROIDS (with or without LABA) and
risk of severe symptoms of COVID-19, including SARS
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Use of ALLERGEN IMMUNOTHERAPY and risk of severe
symptoms of COVID-19, including SARS

























NA LA EU AFR/ME AP
Use of BIOLOGICAL AGENTS and risk of severe symptoms of
COVID-19, including SARS
YES NO I DON'T KNOW OTHER
Fig. 4 Experience of participants of the Allergy & COVID-19 international survey: risk of severe symptoms and treatments used by the
allergy community (NA¼ North America, LA ¼ Latin America, EU ¼ Europe, AFR/ME ¼ Africa and Middle East, AP ¼ Asia Pacific)
12 Tanno et al. World Allergy Organization Journal (2021) 14:100515
http://doi.org/10.1016/j.waojou.2021.100515long-acting-beta agonists can be adjusted for
cases of asthma exacerbation for both adults and
children. For patients with asthma of any severity
who are exhibiting worsening control or an acute
exacerbation, the COVID-19 screening protocols
should be followed in order to determine their
risk.10–13,30–32 Also, patients with allergic rhinitis
and patients treated with AIT were advised to
carry on their treatment.33–36
AIT and biological agents are valued treatment
options for the care of many allergic and hyper-
sensitivity conditions.37 Their use or continuation
should be assessed individually depending on the
status of the patient and the stage of the
treatment.12,34–36,38–42 It is recommended to
avoid starting AIT during the pandemic period,
except for unusual cases of patients with
unavoidable exposure to triggers that have
resulted in anaphylaxis or asthma-related hospital-
ization and there is no other alternative treatment.
For patients receiving injectable inhalant AIT forallergic rhinitis, the schedule can be adapted if
needed, particularly if the patient is in the mainte-
nance phase of the treatment.10,34–36 In order to
follow social distancing recommendations, it also
has been recommended that switching the route
of AIT from subcutaneous to sublingual, either
temporarily or permanently, may be considered
based on the expertise of the allergist.38 The
responses to the survey from those with
experience on managing these specific treatments
during the pandemic agreed that none of them
increased the risk of contacting the infection or
developing SARS. Our survey demonstrated that
the majority (>60%) of the allergy community is
not uniformed about official recommendations
regarding the continuation of AIT and biological
treatment, despite several position papers
available on Pubmed to this matter.
Four main classes of biological agents are
currently (July 2020) approved by the US Food and
Drug Administration (FDA) and European
Volume 14, No. 2, February 2021 13Medicines Agency (EMA) for allergic and hyper-
sensitivity diseases. They are: anti-IgE (Omalizu-
mab), anti-IL5 (Mepolizumab, Reslizumab), anti-
IL4/13 (Dupilumab), and anti-IL5 R (Benralizu-
mab).37–39,43–53 In placebo-controlled trials with
omalizumab, mepolizumab, reslizumab, and
dupilumab in asthmatic patients, no risk of
increased infection susceptibility, or immunosup-
pression was reported to date and, in the case of
omalizumab, there is a possible anti-infectious ef-
fect.12 Up to now, there has been no evidence
suggesting that the immune response to SARS-
CoV-2 should be impaired by the treatment of bi-
ologicals in allergic and hypersensitivity patients.
In the absence of data that would indicate any
potential harm, the therapies should be carried out
during the COVID-19 pandemic in patients with
clear indications for those who have had positive
effect.12
The interaction between viral infection and the
development or worsening of some drug hyper-
sensitivity conditions has been studied over the
last 20 years. Several groups reported the associ-
ation between human herpesvirus 6 reactivation
and some reactions, such as drug reaction with
eosinophilia and systemic symptoms (DRESS). Viral
infections also have been implicated in mimicking,
triggering, or worsening cases of urticaria.
Although drug hypersensitivity (11%) and urticaria
(1.4%) have been self-reported in patients with
COVID-19,21 the majority of our respondents
indicated that the infection may not be a
facilitator for developing a higher proportion of
adverse reactions to AIT and biological agents.
Various drugs being used in different phases of
the disease from SARS-CoV-2 seem to cause rare
but potentially severe drug hypersensitivity re-
actions, mostly non-immediate reactions based on
a limited number of case reports.15
Mortality and morbidity data are key parameters
to guide public health actions, and are crucial in
cases of public health emergencies. International
counting measures are used to harmonize data
and provide global epidemiology. The WHO In-
ternational Classification of Diseases (ICD) is the
foundation for the identification of trends and
statistics globally and is the international standard
for reporting diseases and health conditions,
currently under global implementation.54 It is the
diagnostic classification standard used in themajority of world countries for reporting mortality
and morbidity, supporting decision-making,
observation of reimbursement and resource allo-
cation trends, and keeping track of safety and
quality guidelines.55 Recently, the WHO
Classification and Terminology Unit, proposed
updates in the ICD-1056 and ICD-1157 COVID-19
related situations classification and coding.7 Even
with 48.5% of the survey participants not being
aware of these updates, it is expected that
overall awareness may increase due to the urgent
need of using these international standards in the
outbreak situation.
Remarkable was the implementation and suc-
cess rate of telemedicine in different áreas during
the pandemic. Although the concept of "remote"
patient care has been around for decades, present
circumstances have provided a grand impetus in
that direction with a view to protecting both pa-
tient and caregiver. Additional advantages are
cost-effectiveness, ability to extend access to spe-
cialty services, and potential to help mitigate the
looming physician shortage. Although some dis-
advantages have emerged, such as the limited
technological resources in certain world areas and
the concern with security of patients’ data, tele-
medicine services have been proved to be effec-
tive by the allergy community.
This study presents some limitations. The survey
presented differential response rate by regional
area. However, we considered the quality of re-
sponses received rather than their quantity, and,
most important, we had geographical representa-
tion from all continents. Despite the specific
response rate, the survey represented a unique
opportunity to give voice to allergists from 78
countries. Although this did not affect our overall
data analysis, it may underline the need for allergy
specialty developments in the areas where the
number of responders was low. The rate of re-
sponses may also have been affected by the dy-
namic changes on the geographical distribution of
the pandemic. In some countries, notably China,
the most populous nation in the world, we
received fewer responses than might have been
expected. We hypothesise that recipients may not
have been able to access the survey due to na-
tional regulations prohibiting Google accounts.
Other factors which may have influenced the
response rate include the difficulty in accessing the
14 Tanno et al. World Allergy Organization Journal (2021) 14:100515
http://doi.org/10.1016/j.waojou.2021.100515online questionnaire and difficulties with the En-
glish language. Ideally, the best evidence-based
study to access individual risk of developing
COVID-19 upon SARS-CoV-2 infection for allergic
and/or asthma patients would be large prospec-
tive multinational cohorts, which would require
additional resources, organization, and time, and
this was not the aim of the current study.
Keep fighting COVID-19!
A pandemic response during a global emer-
gency is a highly atypical circumstance having
considerable impact in many sectors of the society,
and in the life of patients and health care pro-
fessionals. We believe that more than providing a
big picture of how allergy is being practiced
worldwide during this highly specific situation due
to the state of emergency, the data presented
intend to be a starting point process of getting
feedback for all recommendations provided by the
allergy societies and the basis of new strategies to
support health professionals while new treatments
and vaccines to COVID-19 are being explored. The
information here presented intends to be helpful
to the community but represents a course of action
during a highly specific situation due to the current
state of the pandemic.
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